Clinical Trials · NCT06256549
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Gan and Lee Pharmaceuticals, USA
- Enrollment
- 272
- Start date
- Aug 2023
- Locations
- 1 site, China
- Primary endpoint
- Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks